Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$10.6 million.

  • Aytu Biopharma's Income from Continuing Operations fell 165190.62% to -$10.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$24.8 million, marking a year-over-year decrease of 53670.01%. This contributed to the annual value of -$14.4 million for FY2025, which is 1499.2% down from last year.
  • Aytu Biopharma's Income from Continuing Operations amounted to -$10.6 million in Q4 2025, which was down 165190.62% from $2.0 million recorded in Q3 2025.
  • Aytu Biopharma's Income from Continuing Operations' 5-year high stood at $3.9 million during Q1 2025, with a 5-year trough of -$53.3 million in Q1 2022.
  • For the 5-year period, Aytu Biopharma's Income from Continuing Operations averaged around -$10.3 million, with its median value being -$6.9 million (2022).
  • The largest annual percentage gain for Aytu Biopharma's Income from Continuing Operations in the last 5 years was 27220.28% (2025), contrasted with its biggest fall of 165190.62% (2025).
  • Quarter analysis of 5 years shows Aytu Biopharma's Income from Continuing Operations stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 108.95% to $599000.0 in 2023, then increased by 13.86% to $682000.0 in 2024, then tumbled by 1651.91% to -$10.6 million in 2025.
  • Its Income from Continuing Operations stands at -$10.6 million for Q4 2025, versus $2.0 million for Q3 2025 and -$20.1 million for Q2 2025.